person · Reporting owner
Carter Paul Rutherford
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP Commercial Ops | August 01, 2016 | August 03, 2016 |
| Immatics N.V.IMTX · Entity 4718 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date August 01, 2016 · Filed August 03, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,305 |
Ending reported balance
After 2016-08-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2016-08-01 · Exercise / conversion · Acquired 1,817 · Balance 64,122 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Row 2 · 2016-08-01 · Exercise / conversion · Acquired 183 · Balance 64,305 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Row 3 · 2016-08-01 · Sale · Disposed 2,000 · Balance 62,305 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.56 · Expires 2023-02-01 | Direct | 4,803 |
Reported balance
After 2016-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-08-01 · Exercise / conversion · Disposed 1,817 · Balance 4,803 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.91 · Expires 2019-07-29 | Direct | 26,043 |
Reported balance
After 2016-08-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-08-01 · Exercise / conversion · Disposed 183 · Balance 26,043 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F3: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Immatics N.V.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.09 · Expires 2036-06-15 | Direct | 48,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 48,000 · Balance 48,000 F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These Options vest 100% on the first anniversary of the grant date, June 16, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALDER BIOPHARMACEUTICALS INC
Report date October 22, 2019 · Filed October 24, 2019
Section 16 reporting ended · disclosed 2019-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.10 · Expires 2025-09-27 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F2: The shares subject to this option shall vest and become exercisable at a rate of one-third of the shares underlying the option on the one-year anniversary of September 28, 2015, the vesting commencement date, one-third of the shares underlying the option on the two-year anniversary of the vesting commencement date and one-third of the shares underlying the option on the three-year anniversary of the vesting commencement date, for so long as the recipient of the option provides continuous service to the issuer, such that the total shares shall be fully vested on the three-year anniversary of the vesting commencement date. The shares subject to this option are fully vested as of the date hereof. F3: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.26 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F3: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor. F4: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.90 · Expires 2027-05-23 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.50 · Expires 2028-05-22 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F7: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.01 · Expires 2029-05-22 | Direct | 0 |
Reported balance
After 2019-10-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-10-22 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F8: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.
F2: The shares subject to this option shall vest and become exercisable at a rate of one-third of the shares underlying the option on the one-year anniversary of September 28, 2015, the vesting commencement date, one-third of the shares underlying the option on the two-year anniversary of the vesting commencement date and one-third of the shares underlying the option on the three-year anniversary of the vesting commencement date, for so long as the recipient of the option provides continuous service to the issuer, such that the total shares shall be fully vested on the three-year anniversary of the vesting commencement date. The shares subject to this option are fully vested as of the date hereof.
F3: The shares subject to this option, whether or not vested, were cancelled at the Effective Time without any consideration payable therefor.
F4: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
F5: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
F6: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.
F7: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
F8: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 1
1 source rowRow 1 · 2022-06-16 · Disposition to issuer · Disposed 20,320 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code.
F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy.
F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 26, 2014 Filed Sep 30, 2014 17:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001179110-14-014622 · edgar.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,240 Underlying: Common Stock · 2,000 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 26, 2014 Filed Sep 30, 2014 17:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $107.47 | $214,945.00 |
DisclosureSEC source: 0001179110-14-014622 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,244 F3 · price: Sale prices reported for the transactions reported here range from $107.47 to $107.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 26, 2014 Filed Sep 30, 2014 17:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,000 | $40.56 | $81,120.00 |
DisclosureSEC source: 0001179110-14-014622 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2014 Filed Aug 28, 2014 18:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.09 | $0.00 |
DisclosureSEC source: 0001179110-14-013357 · edgar.xml · derivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,200 Underlying: Common Stock · 10,000 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| August 26, 2014 Filed Aug 28, 2014 18:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $106.16 | $1,061,618.00 |
DisclosureSEC source: 0001179110-14-013357 · edgar.xml · nonDerivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,244 F3 · price: Sale prices reported for the transactions reported here range from $105.835 to $106.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 26, 2014 Filed Aug 28, 2014 18:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $19.09 | $190,850.00 |
DisclosureSEC source: 0001179110-14-013357 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2014 Filed Aug 28, 2014 18:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 259 | $21.94 | $5,683.73 |
DisclosureSEC source: 0001179110-14-013357 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,244 F1 · kind: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.. Read SEC document |
| August 08, 2014 Filed Aug 12, 2014 20:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,728 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001179110-14-012752 · edgar.xml · derivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,264 Underlying: Common Stock · 16,728 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 08, 2014 Filed Aug 12, 2014 20:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,303 | $92.04 | $119,930.34 |
DisclosureSEC source: 0001179110-14-012752 · edgar.xml · nonDerivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,985 F4 · price: Sale prices reported for the transactions reported here range from $91.98 to $92.14. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 08, 2014 Filed Aug 12, 2014 20:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,425 | $91.54 | $1,411,950.51 |
DisclosureSEC source: 0001179110-14-012752 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,288 F3 · price: Sale prices reported for the transactions reported here range from $90.92 to $91.89. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 08, 2014 Filed Aug 12, 2014 20:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,728 | $26.99 | $451,488.72 |
DisclosureSEC source: 0001179110-14-012752 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2014 Filed Aug 5, 2014 21:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-012445 · edgar.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,300 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 25% every year thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 25% every year thereafter until fully vested. Read SEC document |
| August 01, 2014 Filed Aug 5, 2014 21:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,220 | $91.50 | $111,630.00 |
DisclosureSEC source: 0001179110-14-012445 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,985 Read SEC document |
| August 01, 2014 Filed Aug 5, 2014 21:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-012445 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2014 Filed Jul 10, 2014 17:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,728 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001179110-14-011674 · edgar.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,992 Underlying: Common Stock · 16,728 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| July 08, 2014 Filed Jul 10, 2014 17:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,728 | $86.45 | $1,446,073.71 |
DisclosureSEC source: 0001179110-14-011674 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,705 F3 · price: Sale prices reported for the transactions reported here range from $86.11 to $86.70. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 08, 2014 Filed Jul 10, 2014 17:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,728 | $26.99 | $451,488.72 |
DisclosureSEC source: 0001179110-14-011674 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2014 Filed Jun 11, 2014 16:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,728 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001179110-14-010139 · edgar.xml · derivative · entry 5 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,720 Underlying: Common Stock · 16,728 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| June 09, 2014 Filed Jun 11, 2014 16:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $80.89 | $161,772.20 |
DisclosureSEC source: 0001179110-14-010139 · edgar.xml · nonDerivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,705 F5 · price: Sale prices reported for the transactions reported here range from $80.69 to $81.08375. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 09, 2014 Filed Jun 11, 2014 16:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,020 | $80.04 | $161,689.89 |
DisclosureSEC source: 0001179110-14-010139 · edgar.xml · nonDerivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,705 F4 · price: Sale prices reported for the transactions reported here range from $79.59 to $80.51. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 09, 2014 Filed Jun 11, 2014 16:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 12,708 | $79.10 | $1,005,182.47 |
DisclosureSEC source: 0001179110-14-010139 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,725 F3 · price: Sale prices reported for the transactions reported here range from $78.57 to $79.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 09, 2014 Filed Jun 11, 2014 16:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,728 | $26.99 | $451,488.72 |
DisclosureSEC source: 0001179110-14-010139 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2014 Filed May 13, 2014 18:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-008268 · edgar.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 25% every year thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 25% every year thereafter until fully vested. Read SEC document |
| May 10, 2014 Filed May 13, 2014 18:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 2,857 | $79.76 | $227,874.32 |
DisclosureSEC source: 0001179110-14-008268 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,433 Read SEC document |
| May 10, 2014 Filed May 13, 2014 18:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-008268 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2014 Filed May 12, 2014 19:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,728 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001179110-14-008187 · edgar.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,448 Underlying: Common Stock · 16,728 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 08, 2014 Filed May 12, 2014 19:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,728 | $78.80 | $1,318,142.98 |
DisclosureSEC source: 0001179110-14-008187 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,562 F3 · price: Sale prices reported for the transactions reported here range from $78.70 to $79.00. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 08, 2014 Filed May 12, 2014 19:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,728 | $26.99 | $451,488.72 |
DisclosureSEC source: 0001179110-14-008187 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 19:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,824 | $0.00 Strike: $26.99 | $0.00 |
DisclosureSEC source: 0001179110-14-006697 · edgar.xml · derivative · entry 6 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,176 Underlying: Common Stock · 8,824 shares Expires 2018-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 19:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,904 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001179110-14-006697 · edgar.xml · derivative · entry 5 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,904 shares Expires 2018-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 19:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,328 | $70.20 | $444,204.72 |
DisclosureSEC source: 0001179110-14-006697 · edgar.xml · nonDerivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,562 F4 · price: Sale prices reported for the transactions reported here range from $69.53 to $70.52. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 19:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,400 | $70.73 | $735,577.44 |
DisclosureSEC source: 0001179110-14-006697 · edgar.xml · nonDerivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,890 F3 · price: Sale prices reported for the transactions reported here range from $70.56 to $71.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 19:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,824 | $26.99 | $238,159.76 |
DisclosureSEC source: 0001179110-14-006697 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2014 Filed Apr 10, 2014 19:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 7,904 | $21.58 | $170,528.80 |
DisclosureSEC source: 0001179110-14-006697 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2014 Filed Mar 12, 2014 17:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,728 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001179110-14-005065 · edgar.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,904 Underlying: Common Stock · 16,728 shares Expires 2018-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2014 Filed Mar 12, 2014 17:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,728 | $79.32 | $1,326,833.18 |
DisclosureSEC source: 0001179110-14-005065 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,562 F3 · price: Sale prices reported for the transactions reported here range from $79.10 to $79.57. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 10, 2014 Filed Mar 12, 2014 17:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,728 | $21.58 | $360,906.60 |
DisclosureSEC source: 0001179110-14-005065 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 11,280 | $79.92 | $901,497.60 |
DisclosureSEC source: 0001179110-14-004891 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,562 Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-004891 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,842 F1 · shares: Vesting of performance share awards on March 6, 2014 Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 19:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001179110-14-004206 · edgar.xml · derivative · entry 6 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 30,000 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 19:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001179110-14-004206 · edgar.xml · derivative · entry 5 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 19:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 99,000 | $83.55 | $8,271,935.10 |
DisclosureSEC source: 0001179110-14-004206 · edgar.xml · nonDerivative · entry 4 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,842 F3 · price: Sale prices reported for the transactions reported here range from $83.50 to $83.67. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 19:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 30,000 | $24.91 | $747,150.00 |
DisclosureSEC source: 0001179110-14-004206 · edgar.xml · nonDerivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 19:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 69,000 | $23.60 | $1,628,400.00 |
DisclosureSEC source: 0001179110-14-004206 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2014 Filed Mar 4, 2014 19:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 709 | $21.94 | $15,558.93 |
DisclosureSEC source: 0001179110-14-004206 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,842 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 10, 2014 Filed Feb 12, 2014 21:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,728 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001179110-14-002591 · edgar.xml · derivative · entry 3 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,632 Underlying: Common Stock · 16,728 shares Expires 2018-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| February 10, 2014 Filed Feb 12, 2014 21:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,728 | $79.10 | $1,323,198.18 |
DisclosureSEC source: 0001179110-14-002591 · edgar.xml · nonDerivative · entry 2 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,133 F3 · price: Sale prices reported for the transactions reported here range from $78.86 to $79.27. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 10, 2014 Filed Feb 12, 2014 21:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,728 | $21.58 | $360,906.60 |
DisclosureSEC source: 0001179110-14-002591 · edgar.xml · nonDerivative · entry 1 Carter Paul Rutherford · CIK 0001600041 · EVP Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.